logo
Plus   Neg
Share
Email

AstraZeneca To Sell Rights To Hypertension Medicines To Atnahs Pharma

AstraZeneca (AZN.L,AZN) agreed to sell the global commercial rights to Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharma. The medicines, used primarily to treat hypertension, have lost their patent protection globally.

AstraZeneca expects to complete the divestment in the first quarter of 2020.

Atnahs will make an upfront payment of $350 million to AstraZeneca. AstraZeneca may also receive future sales-contingent payments of up to $40 million between 2020 and 2022.

The agreement excludes the rights in the US and India, which were previously divested, and in Japan, which will be retained by AstraZeneca.

The company noted that it will continue to manufacture and supply Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs during a transition period.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Video streaming giant Netflix said it will donate 1 million euros to Audiens, the social protection group of the French cultural sector, to help launch a COVID-19 emergency relief fund to support workers in the French television and cinema industry. Netflix and Audiens said they have created the new COVID-19 Film and TV Emergency Relief Fund to help the hardest hit workers in the industry. Major U.S. retail container ports are estimated to report a five-year low for imports in March as consumer demand has been impacted with millions of Americans out of work amid the coronavirus (COVID-19) outbreak, according to a report by the National Retail Federation or NRF. The U.S. Food and Drug Administration has issued warning letters to three sellers of fraudulent COVID-19 products. There are currently no approved preventatives or treatments for COVID-19, the FDA said in a statement.
Follow RTT
>